Trials / Completed
CompletedNCT03925441
Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea
Post-Marketing Surveillance Study of Adalimumab (Humira) for Pediatric Chronic Severe Plaque Psoriasis Patients According to the Standard for "Re-Examination of New Drugs"
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 4 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the real world safety and effectiveness of adalimumab (Humira) for the treatment of Korean patients with pediatric chronic severe plaque psoriasis under a routine treatment practice.
Conditions
Timeline
- Start date
- 2019-06-25
- Primary completion
- 2019-08-06
- Completion
- 2019-08-06
- First posted
- 2019-04-24
- Last updated
- 2020-06-12
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03925441. Inclusion in this directory is not an endorsement.